IPG Photonics (IPGP) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
1 Apr, 2026Executive summary
Annual meeting scheduled for May 12, 2026, at 377 Simarano Drive, Marlborough, MA, at 10:00 AM EDT.
Shareholders can vote online, by phone, email, or in person with a legal proxy.
Proxy materials and annual report are available online, with options for electronic or paper delivery upon request by May 1, 2026.
Voting matters and shareholder proposals
Election of ten directors: Gregory Beecher, Jeanmarie Desmond, Gregory Dougherty, Mark Gitin, Kolleen Kennedy, Eric Meurice, Natalia Pavlova, John Peeler, Eugene Scherbakov, and Agnes Tang.
Advisory vote on executive compensation (say-on-pay) is on the agenda.
Ratification of Deloitte & Touche LLP as independent registered public accounting firm for 2026.
Board recommends voting FOR all director nominees and both proposals.
Other business may be addressed if properly brought before the meeting.
Board of directors and corporate governance
Board nominees include a mix of experienced professionals and current directors.
Board provides recommendations on all voting items.
Latest events from IPG Photonics
- Q2 2026 revenue up 11% with strong industrial demand, margin gains, and Lumibird Medical deal.IPGP
Q2 20264 Aug 2026 - €300M acquisition expands medical laser leadership, adds $1B market, and targets Q4 2026 close.IPGP
M&A announcement17 Jul 2026 - Q3 revenue declined 23% and net loss reached $233.6M, but adjusted EPS was $0.29.IPGP
Q3 20248 Jul 2026 - Q1 revenue beat guidance despite a 10% drop, with strong bookings and tariff-related Q2 risks.IPGP
Q1 20258 Jul 2026 - Revenue up 17% year-over-year, led by Industrial Solutions, but net income declined on higher costs.IPGP
Q1 20265 May 2026 - Growth, compensation realignment, and board-backed proposals mark a transformative year.IPGP
Proxy filing5 May 2026 - 2025 saw revenue growth, strong governance, performance-based pay, and expanded ESG oversight.IPGP
Proxy filing1 Apr 2026 - Growth driven by innovation, new markets, and strong financials positions the business for expansion.IPGP
47th Annual Raymond James Institutional Investor Conference2 Mar 2026 - Q4 revenue up 17% year-over-year, with strong gains in medical and advanced applications.IPGP
Q4 202512 Feb 2026